JOHN KIRKWOOD to Quality of Life
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Quality of Life.
Connection Strength
0.924
-
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. Eur J Cancer. 2022 11; 176:207-217.
Score: 0.415
-
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study. Immunotherapy. 2024 01; 16(1):29-42.
Score: 0.112
-
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):251-260.
Score: 0.106
-
Patient-reported tolerability of adjuvant ipilimumab (3 or 10?mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan; 32(1):183-196.
Score: 0.103
-
Survival benefit in melanoma. J Clin Oncol. 1998 Jan; 16(1):388-9.
Score: 0.075
-
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002 Mar 01; 20(5):1311-8.
Score: 0.025
-
Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
Score: 0.022
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
Score: 0.020
-
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
Score: 0.017
-
Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up. Health Psychol. 1992; 11(6):349-54.
Score: 0.012
-
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
Score: 0.006
-
Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res. 2000 Aug; 9(3):352-63.
Score: 0.006
-
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997 Jun; 15(6):2351-8.
Score: 0.004